Merck’s latest Type 2 diabetes deal uses innovative enzyme selection tech
The ongoing effort to develop better drugs to address the $250 billion problem of Type 2 diabetes has a new development. Merck (NYSE: MRK) is collaborating with Abide Therapeutics on three drugs based on a technology platform that selectively chooses from a group of enzymes that have broad therapeutic applications. The collaboration, which will also […]